Tenaya Therapeutics, Inc. Payments to Acquire Marketable Securities
Tenaya Therapeutics, Inc. (TNYA) reported Payments to Acquire Marketable Securities of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-03-11
- Tenaya Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Tenaya Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2024-12-31 was $2.01M, a 87.15% decline year-over-year.
- Tenaya Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2024-09-30 was $50.61M.
- Tenaya Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2024-06-30 was $10.81M, a 28.89% decline year-over-year.
- Tenaya Therapeutics, Inc. payments to acquire marketable securities for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Tenaya Therapeutics, Inc. payments to acquire marketable securities for fiscal 2024 was $87.07M, a 53.71% increase from fiscal 2023.
- Tenaya Therapeutics, Inc. payments to acquire marketable securities for fiscal 2023 was $56.64M, a 59.68% decline from fiscal 2022.
- Tenaya Therapeutics, Inc. payments to acquire marketable securities for fiscal 2022 was $140.48M, a 34.19% decline from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $0.00 10-K · filed 2026-03-11 | ||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-10 | |||
| 2024-12-31 | $2.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $52.62M derived: sum of 2 quarters · filed 2026-03-11 | $63.43M derived: sum of 3 quarters · filed 2026-03-11 | $87.07M 10-K · filed 2026-03-11 |
| 2024-09-30 | $50.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $61.41M derived: sum of 2 quarters · filed 2025-11-10 | $85.06M 10-Q · filed 2025-11-10 | $100.70M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $10.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $34.45M 10-Q · filed 2025-08-06 | $50.10M derived: sum of 3 quarters · filed 2025-08-06 | $50.10M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $23.64M 10-Q · filed 2025-05-07 | $39.29M derived: sum of 2 quarters · filed 2025-05-07 | $39.29M derived: sum of 3 quarters · filed 2025-05-07 | $54.49M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $15.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $15.65M derived: sum of 2 quarters · filed 2025-03-10 | $30.85M derived: sum of 3 quarters · filed 2025-03-10 | $56.64M 10-K · filed 2025-03-10 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $15.20M derived: sum of 2 quarters · filed 2024-11-06 | $41.00M 10-Q · filed 2024-11-06 | $72.74M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $15.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $41.00M 10-Q · filed 2024-08-08 | $72.74M derived: sum of 3 quarters · filed 2024-08-08 | $116.34M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $25.80M 10-Q · filed 2024-05-14 | $57.54M derived: sum of 2 quarters · filed 2024-05-14 | $101.14M derived: sum of 3 quarters · filed 2024-05-14 | $123.10M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $31.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $75.34M derived: sum of 2 quarters · filed 2024-03-18 | $97.31M derived: sum of 3 quarters · filed 2024-03-18 | $140.48M 10-K · filed 2024-03-18 |
| 2022-09-30 | $43.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $65.57M derived: sum of 2 quarters · filed 2023-11-08 | $108.74M 10-Q · filed 2023-11-08 | $158.76M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $21.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $65.14M 10-Q · filed 2023-08-09 | $115.16M derived: sum of 3 quarters · filed 2023-08-09 | |
| 2022-03-31 | $43.17M 10-Q · filed 2023-05-10 | $93.20M derived: sum of 2 quarters · filed 2023-05-10 | ||
| 2021-12-31 | $50.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $213.44M 10-K · filed 2023-03-08 | ||
| 2021-09-30 | $163.42M 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |